NCT01396213View on ClinicalTrials.gov

A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

342

Participants

Timeline

Start Date

November 7, 2011

Primary Completion Date

August 20, 2013

Study Completion Date

August 20, 2013

Conditions
Celiac Disease
Interventions
DRUG

Larazotide Acetate

gelatin capsule

DRUG

placebo

gelatin capsule

Trial Locations (62)

10016

New York

10032

New York

11042

Lake Success

14618

Rochester

15243

Pittsburgh

18017

Bethlehem

18944

Perkasie

19107

Philadelphia

21229

Baltimore

21742

Hagerstown

22304

Alexandria

22911

Charlottesville

27103

Winston-Salem

27518

Cary

28144

Salisbury

30067

Marietta

32132

Edgewater

32806

Orlando

33426

Boynton Beach

34491

Summerfield

35209

Birmingham

37421

Chattanooga

39202

Jackson

40202

Louisville

40536

Lexington

44060

Mentor

44195

Cleveland

48047

Chesterfield

49519

Wyoming

50266

West Des Moines

55805

Duluth

55905

Rochester

59808

Missoula

60612

Chicago

61107

Rockford

63141

St Louis

67207

Wichita

73160

Oklahoma City

75321

Dallas

78229

San Antonio

80222

Denver

84109

Salt Lake City

84790

St. George

85206

Mesa

85704

Tucson

89119

Las Vegas

90404

Santa Monica

92056

Oceanside

92868

Orange

94115

San Francisco

94598

Walnut Creek

97210

Portland

98104

Seattle

02215

Boston

08053

Marlton

02886

Warwick

T6G2X8

Edmonton

V2T3R7

Abbotsford

V1Y1Z9

Kelowna

V6Z2K5

Vancouver

V8V3P9

Victoria

L854J9

Hamilton

Sponsors
All Listed Sponsors
collaborator

Teva Pharmaceuticals USA

INDUSTRY

lead

9 Meters Biopharma, Inc.

INDUSTRY

NCT01396213 - A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease | Biotech Hunter | Biotech Hunter